Peptide Intel
Regulatory updates, research breakdowns, and market intelligence.
FDA-Approved Peptides: The Complete List (2026)
A comprehensive, evidence-grounded list of every FDA-approved peptide and peptide-based drug — what it does, what it's approved for, and how it compares to the compounded versions circulating online.
10 min · 2026-05-15 · Ercle Editorial
GHK-Cu in Dermatology: Reading Past the Marketing
GHK-Cu has legitimate peer-reviewed RCT data for skin aging. Separate what the clinical trials showed from the supplemen...
4 min · 2026-05-17
ResearchBPC-157 and Gut Health: Reviewing the IBD and NSAID Injury Evidence
BPC-157's strongest preclinical evidence is gut-related. Cover the stomach pentadecapeptide origin, colitis models, NSAI...
3 min · 2026-05-16
ResearchRetatrutide: The Triple Agonist After Tirzepatide and What the Phase II Data Shows
Eli Lilly's LY3437943 hits GLP-1, GIP, and glucagon receptors. Cover the SURMOUNT Phase II results, weight loss %, and h...
3 min · 2026-05-14
RegulatoryFDA Advisory Panel to Review Seven Peptides in July 2026: What Prescribers Need to Know
The FDA's April 2026 notice announced a July advisory panel review of BPC-157, TB-500, AOD-9604, Thymosin Alpha-1, CJC-1295, Ipamorelin, and Epithalon. Here's what the review means, what outcomes are possible, and what practitioners should watch for.
7 min · 2026-05-13
ResearchSemaglutide vs. Tirzepatide: What the Latest Head-to-Head Data Actually Shows
Compare STEP vs SURMOUNT trial outcomes, weight loss %, cardiovascular endpoints, tolerability profiles. No marketing sp...
3 min · 2026-05-13
ClinicalThe Complete GLP-1 Class Comparison: Semaglutide vs. Tirzepatide vs. Retatrutide vs. CagriSema
A practitioner-focused breakdown of the GLP-1 drug class as of 2025: mechanism differences, efficacy comparisons, safety profiles, and what the pipeline looks like.
12 min · 2026-01-12
RegulatoryThe GLP-1 Compounding Crackdown: What Prescribers and Patients Need to Know
The FDA removed semaglutide and tirzepatide from shortage lists in 2024, triggering the end of legal compounding. Here's what happened, what the enforcement timeline looks like, and what comes next.
8 min · 2026-01-10
RegulatoryBPC-157 Regulatory Status in 2025: What Changed and What It Means
BPC-157 was never on the FDA's 503A bulk substances list and FDA actions have repeatedly targeted vendors. Here's a clear-eyed look at the legal status, why clinicians continue to use it, and the risk calculus.
6 min · 2026-01-08
ResearchHow Ercle Rates Peptide Evidence: Our Methodology
We use a four-tier evidence rating system. Here's exactly what each rating means, what disqualifies compounds from higher ratings, and why we rate the way we do.
5 min · 2026-01-05
RegulatoryThe Regulatory Status of Research Peptides: A Practitioner's Primer
503A, 503B, the bulk substances list, research-only, FDA-approved — what do these terms actually mean for practitioners prescribing peptides?
9 min · 2026-01-03